Physician profile
Henry Nasrallah
NPI 1346386307
$3,769,307.34
in general payments reported to CMS, 2019-2025
22 companies · $762K in 2025
The $762K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580K · 2020: $296K · 2021: $230K · 2022: $445K · 2023: $669K · 2024: $788K · 2025: $762K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.4M · Consulting Fee: $345K · Travel and Lodging: $304K · Honoraria: $114K · Food and Beverage: $36K · Education: $8.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,419,634.77 |
| Consulting Fee | $345,302.25 |
| Travel and Lodging | $304,347.83 |
| Honoraria | $113,556.50 |
| Food and Beverage | $35,779.45 |
| Education | $8.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $693,718.65 | 2019-2025 | Invega Sustenna, Invega Trinza, Invega |
| Teva Pharmaceuticals USA, INC. | $525,969.91 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $488,130.01 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $416,975.80 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $411,273.79 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $291,189.71 | 2022-2025 | Auvelity |
| Alkermes, INC. | $280,166.63 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $185,330.59 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $146,841.58 | 2019-2024 | Nuplazid |
| Indivior INC. | $74,793.01 | 2019-2023 | Perseris |
| Allergan, INC. | $70,356.72 | 2019-2020 | |
| Abbvie INC. | $49,567.09 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $36,637.26 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22,145.85 | 2022-2025 | |
| Boehringer Ingelheim International Gmbh | $19,907.05 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $15,185.50 | 2019-2022 | |
| Eisai INC. | $13,812.08 | 2019-2020 | |
| Noven Pharmaceuticals, INC. | $13,276.00 | 2020-2022 | |
| Livanova USA, INC. | $7,779.94 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Avanir Pharmaceuticals, INC. | $3,100.00 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,029.00 | 2019-2025 | |
| Luye Pharma (USA) Ltd. | $121.17 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Nasrallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.